Page 1

KEROS THERAPEUTICS Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results November 4 , 2021 1:03 PM EDT LEXINGTON , Mass . , Nov. 04 , 2021 ( GLOBE NEWSWIRE ) -- Keros Therapeutics , Inc. ( " Keros " or the " Company " ) ( Nasdaq : KROS ) , a clinical - stage biopharmaceutical company focused on the discovery , development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need , today provided a business update and reported financial results for the quarter ended September 30 , 2021 . " As we enter the last quarter of the year , we are approaching the conclusion of Part 1 of our Phase 2 clinical trial of KER - 050 in patients with myelodysplastic syndromes ( " MDS " ) . In preparation for Part 2 of this trial , we are excited to bring on additional clinical sites to increase patient recruitment , and look forward to providing a clinical data update at the 63rd American Society of Hematology ( " ASH " ) Annual Meeting and Exposition held December 11 through 14 , " said Jasbir S. Seehra , Ph.D. , President and Chief Executive Officer . " As we look to the remainder of 2021 and into 2022 , I am very excited by the potential of the company as we continue to advance and expand our pipeline across a wide range of serious hematological and musculoskeletal disorders . " Recent Corporate Highlights : • Entrance into lease for new headquarters : In September 2021 , the Company announced that it entered into an indenture of lease with Revolution Labs Owner , LLC , pursuant to which the Company will lease approximately 35,662 square feet of office and laboratory space located at 1050 Waltham Street , Lexington , Massachusetts for its new principal executive office . The Company expects to move into its new headquarters in the fourth quarter of 2022 . Recent Program Highlights : • KER - 050 for the treatment of ineffective hematopoiesis to address cytopenias • Keros will present an abstract announcing additional preliminary results from Keros ' Phase 2 clinical trial of KER - 050 in patients with very low- , low- , or intermediate - risk MDS at the 63rd ASH Annual Meeting and Exposition , to be held both in person and virtually from December 11 through 14 , 2021 . o Keros has initiated dosing for Cohort 4 of its Phase 2 clinical trial of KER - 050 at 3.75 mg / kg of KER - 050 , to be administered once every four weeks for 12 weeks , following Safety Review Committee recommendation . • KER - 012 for the treatment of disorders associated with bone loss and for the treatment of pulmonary arterial hypertension o In September 2021 , the Company commenced a randomized , double - blind , placebo- controlled , two - part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER - 012 in healthy volunteers . Keros expects to report initial data from Part 1 of this trial in the first half of 2022 and additional data from Part 2 of this trial in the second half of 2022 . Third Quarter 2021 Financial Results Keros reported a net loss of $ 20.3 million in the third quarter of 2021 as compared to a net loss of $ 12.0 million in the third quarter of 2020. The increase in net loss for the third quarter was largely due to increased research and development efforts as well as additional infrastructure expenses to support the achievement of Keros ' corporate goals . Research and development expenses were $ 14.8 million for the third quarter of 2021 as compared to $ 8.4 million for the same period in 2020. The increase of $ 6.4 million was primarily due to additional research and development efforts , manufacturing activities , and personnel expenses to support the advancement of Keros ' pipeline . General and administrative expenses were $ 5.4 million for the third quarter of 2021 as compared to $ 3.6 million for the same period in 2020. The increase of $ 1.8 million was primarily due to increase in personnel expenses and other external expenses to support Keros ' organizational growth .